Is there a cure for corporate crime in the drug industry

BMJ (Online)

Volumn 346, Issue 7894, 2013, Pages

  Davis, Courtney ^a   Abraham, John ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BENFLUOREX; GABAPENTIN; PAROXETINE;

ARTICLE; BUSINESS ETHICS; CORPORATE CRIME; CRIME; CRIMINAL BEHAVIOR; DRUG APPROVAL; DRUG INDUSTRY; DRUG LEGISLATION; DRUG MANUFACTURE; DRUG MARKETING; EUROPEAN UNION; FOOD AND DRUG ADMINISTRATION; GOVERNMENT; GOVERNMENT REGULATION; HEALTH CARE ORGANIZATION; HUMAN; LAW; LAW ENFORCEMENT; MEDICINES AND HEALTHCARE PRODUCTS REGULATORY AGENCY; PRESCRIPTION; PRIORITY JOURNAL; PUBLIC HEALTH; PUNISHMENT; UNITED STATES;

DRUG INDUSTRY; FRAUD; HUMANS; MARKETING; SCIENTIFIC MISCONDUCT;

EID: 84873616097     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.f755     Document Type: Article

References (13)

1. Gøtzsche PC. Big pharma often commits corporate crime, and this must be stopped. BMJ 2012;345:e8462.
2. Kesselheim AS, Mello MM, Studdert DM. Strategies and practices in off-label marketing of pharmaceuticals: a retrospective analysis of whistleblower complaints. PLoS Med 2011;8:1-9.
3. US Department of Justice. GlaxoSmithKline to plead guilty and pay $3 billion to resolve fraud allegations and failure to report safety data. 2012. Press release. www.justice.gov/opa/pr/2012/July/12-civ-842.html.
4. Kennedy K. Experts seek alternatives to excluding drug companies. USA Today 2012 March 5. http://usatoday30.usatoday.com/news/washington/story/2012- 03-05/penaltiesdrug-companies/53372918/1.
5. Kesselheim AS, Darby D, Studdert DM, Glynn R, Levin R, Avorn J. False Claims Act prosecution did not deter off-label drug use in the case of Neurontin. Health Affairs 2011;30:2318-27.
6. US Government Accountability Office. FDA's oversight of the promotion of drugs for off-label uses. 2008, GAO-08-835. www.gao.gov/products/GAO-08-835.
7. Medicines and Healthcare Products Regulatory Agency. MHRA investigation into Glaxosmithkline/Seroxat. 2008. www.mhra.gov.uk/home/groups/es-policy/ documents/websiteresources/con014155.pdf.
8. Medicines and Healthcare Products Regulatory Agency. Delivering high standards in medicines advertising regulation. Sixth annual report January-December 2011. www. mhra.gov.uk/home/groups/comms-ic/documents/ websiteresources/con143738.pdf.
9. US Committee on Energy and Commerce, House of Representatives. Ketek clinical study fraud: what did Aventis know?' 2008. www.gpo.gov/fdsys/pkg/CHRG- 110hhrg48587/pdf/CHRG-110hhrg48587.pdf.
10. Abraham J, Davis C. Interpellative sociology of pharmaceuticals: problems and challenges for innovation and regulation in the 21st century. Technol Anal Strategic Manage 2007;19:387-402.
11. Skadden. FDA Revamps Criminal Prosecution Guidelines and Expands Health Care Fraud-Related Investigations. 2011. https://www.skadden.com/sites/default/ files/publications/FDA-Revamps-Criminal-Prosecution-Guidelines-0.pdf.
12. European Medicines Agency. European Medicines Agency acts on deficiencies in Roche medicines-safety reporting. EMA/405725/2012. 2012. www.ema.europa.eu/docs/en-GB/document-library/Press-release/2012/06/WC500129047. pdf.
13. Reuters. France Servier founder investigated in drug deaths. 2012. www.reuters.com/article/2012/12/11/france-mediator-idUSL5E8NBGI520121211